Loss of genetic material from chromosome arm 8p occurs commonly in breast carcinomas, suggesting that this region is the site of one or more tumor-suppressor genes (TSGs). Comparative genomic hybridization analysis showed that 8p loss is more common in breast cancers from pre-menopausal compared with post-menopausal patients, as well as in high-grade breast cancers, regardless of the menopausal status. Subsequent highresolution gene expression profiling of genes mapped to chromosome arm 8p, on an extended cohort of clinical tumor samples, indicated a similar dichotomy of breast cancer clinicopathologic types. Some of these genes showed differential downregulation in early-onset and later-onset, high-grade cancers compared with lowergrade, later-onset cancers. Three such genes were analysed further by in situ technologies, performed on tissue microarrays representing breast tumor and normal tissue samples. PCM1, which encodes a centrosomal protein, and DUSP4/MKP-2, which encodes a MAP kinase phosphatase, both showed frequent gene and protein loss in carcinomas. In contrast, there was an excess of cases showing loss of expression in the absence of reduced gene copy number of SFRP1, which encodes a dominant-negative receptor for Wnt-family ligands. These candidate TSGs may constitute some of the molecular drivers of chromosome arm 8p loss in breast carcinogenesis. Oncogene (2004) Loss of part or all of chromosome arm 8p occurs commonly in breast carcinomas (including poor-prognosis tumors), as well as in other cancer types, indicating that this region may harbor one or more tumorsuppressor genes (TSGs) (Radford et al., 1995; Yokota et al., 1999; Sigbjornsdottir et al., 2000; Thor et al., 2002) . However, the molecular drivers of the 8p loss remain to be clearly established. Early-onset, premenopausal breast cancers frequently have more adverse prognostic factors than post-menopausal cancers, including high proliferation rates and negative hormone receptor status (Marcus et al., 1994; Walker et al., 1996; Kollias et al., 1997; Lai et al., 2002) , as well as different epidemiological risk factors (Ishibe et al., 1998; Xiong et al., 2001; Band et al., 2002) . These pathobiological and epidemiological differences likely reflect different molecular pathogenic pathways in many early-onset versus later-onset breast cancers.
To identify the different molecular pathogenetic drivers between these breast cancer subtypes on a genomic scale, we performed conventional CGH analysis on a cohort of 65 invasive breast carcinomas. In all, 33 were from clinically pre-menopausal patients and 32 were from post-menopausal patients ( Table 1 ). The only differences in chromosomal distribution of copy number changes by menopausal status were loss of 8p and 16q, which were more common in pre-menopausal patients. 8p loss was detected in 42% of ER-negative cancers (16/38) and 19% of ER-positive cancers (5/27; P ¼ 0.06). A generalized linear statistical model (Venables and Ripley, 2002) was used to test the joint effect of menopausal status, tumor grade and ER status with 8p loss. Overall, 8p loss was most common in premenopausal patients or post-menopausal patients with high-grade (Grade 3) cancers, and in ER-negative tumors, with the log likelihood ratio of w 2 significant at the 5% level in each case. It was not possible to dissociate the effects of ER and menopausal status, as these two factors were so closely associated. The minimal region of 8p loss was 8p12-21, while 52% of cases (11 of 21) showed deletion of the entire chromosome arm. Gain of chromosome arm 8p was seen in only two of the 65 cases (3%), both of which were post-menopausal.
We then sought to identify the individual genes affected by these 8p copy number alterations by performing gene expression analysis on an extended cohort of 53 primary breast cancers, using custom Affymetrix GeneChip s DNA microarrays (Glynne et al., 2000) . A subset of eight of these tumors had also been evaluated in the original CGH analysis. Of the 194 unique (at the time of array design) 8p transcripts represented on the GeneChip s , 153 showed some variation among tumor samples. Unsupervised hierarchical cluster analysis on these 153 probe sets and 53 tumor samples (Figure 1 ) split the tumors into two major clusters. The majority of early-onset cancers (i.e., p45 years) and later-onset (X55 years), grade 3 cancers clustered together (72%; that is, 21 of 29 early-onset and later-onset, grade 3 reside in tumor cluster #1) and the majority of grade 1 and 2 later-onset cancers clustered together (71%; that is, 17 of 24 later-onset/grade 1 and 2 reside in tumor cluster #2). This nonrandom segregation suggests an underlying difference in 8p gene expression dependent on age of tumor onset and grade (P ¼ 0.002). ER status, detected by IHC, was available for 45 of these cases. In all, 79% of Cluster #1 (19 of 24) were ER negative, compared with 48% of cluster #2 (10 of 21; P ¼ 0.03). Hence, a similar dichotomy of breast cancer types, reflecting the age of onset, tumor grade and ER status, was determined by both CGH analysis of 8p copy number and by mRNA expression analysis of 8p genes.
Unsupervised hierarchical clustering of 8p gene expression in the 53 tumors revealed two major groups: one defined by the upper major branch point on the vertical axis (Figure 1a ), dominated by genes with high expression across the majority of tumors, and a lower group characterized by genes with low expression in most tumors (Pp0.0001). Further cluster analysis identified three subgroups of genes in the lower group (Figure 1a) . Two of these subgroups (labeled A and B) showed low expression in tumors of cluster #1, compared with cluster #2. The third group (C) showed generally low levels of expression across all tumors, but high expression in some tumors in cluster #1. The identifiers of genes within groups A and B are shown in Figure 1b and c.
An independent analysis was performed on the 153 transcripts by dividing the 53 tumors according to age of onset and tumor grade. In total, 22 genes showed lower expression in early-onset and high-grade cancers compared with later-onset and low-grade cancers at the P ¼ 0.05 level. All but one of these genes (21 of 22; 96%) 
Differences in the total number of changes in two groups were tested by the non-parametric Mann-Whitney U test. Differences in the proportions of individual chromosomal changes between two groups were tested with Fisher's exact test. NS ¼ P-value 40.05. CGH methods have been previously described (Allen et al., 2000) Figure 1 were found in the two gene subgroups previously determined by unsupervised clustering to have reduced expression in tumor cluster #1 compared with tumor cluster #2.
We used dual-color FISH analysis employing genespecific BAC probes and an 8p centromere-specific probe on TMAs, to evaluate whether the decreased gene expression seen in cluster #1 tumours was related to gene copy number changes. The genes PCM1, DUSP4/ MKP-2 and SFRP1 were evaluated as potential TSGs, based on our experimental findings (their lower expression in cluster #1 compared to cluster #2), taken together with information on these genes in the literature (Figure 2 ). SFRP1 had been previously described as a TSG in breast cancer, but with little or no indication as to its differential expression in cancer subtypes. The two remaining genes had not been postulated as TSGs in breast cancer; PCM1 has been described as a TSG inactivated by translocation in thyroid papillary cancer (Corvi et al., 2000) , while DUSP4/MKP-2 is a dual-specificity phosphatase, similar in function to the TSG PTEN (Waite and Eng, 2002) .
The FISH data were expressed as ratios of the two probes in individual tumors (Konig et al., 1999) , with the centromeric probe acting as a surrogate for standardization of the number of cells counted in an individual tumor. PCM1, DUSP4/MKP-2 and SPFR1 relative gene copy number loss was seen in 45% (15/33), 23% (8/35) and 13% (6/47) of scorable cases, respectively. FISH was performed successfully for all three probes in 21 individual cases (Figure 2b) . The most common combination of gene copy number status within individual cancers was either no loss of any of the probes compared with the centromeric probe (11 cases) or loss of PCM1 only (three cases), or loss of both DUSP4/MKP-2 and PCM1, but no loss of SFRP1 (three cases). Only one case showed loss of all three genes (Figure 2b, c) . The ratio ranges of specific BAC gene probes compared with centromeric probe through the 21 tumors were 0.07-1.06, 0.12-0.9 and 0.32-0.99 for PCM1, DUSP4/MKP-2 and SFRP1, respectively.
We used in situ analysis of mRNA and/or protein on TMAs, in order to compare the gene copy number with the expression of the gene product. Of 103 cases, 45 (43%) showed loss of SFRP1 expression by ISH (Figure 3a) . Out of these 103 cases, 42 also had gene copy number analysis by FISH. There was an excess percentage of cases showing gene expression loss by ISH compared with copy number loss by FISH (i.e. 43 versus 14%). Additionally, 29% (12/42) of tumors with normal gene copy number detected by FISH had loss of gene expression by ISH. Our data suggest that reduced expression was more common than gene copy number loss, and hence mechanisms other than gene deletion may be important in reducing the expression of the SFRP1 protein, a dominant-negative receptor for Wnt-family member ligands (Melkonyan et al., 1997; Zhou et al., 1998; Ugolini et al., 1999) . The findings of other groups support the potential for gene silencing of the SFRP1 promoter as one mechanism accounting for this phenomenon (Zhou et al., 1998; Suzuki et al., 2002) .
Loss of PCM1 protein by IHC was seen in 31% of tumor samples (36/115) (Figure 3b ). Both PCM1 protein and gene copy number data were available on 30 cases. PCM1 protein was present in 94% (15 of 16) of cases with normal gene copy number detected by FISH, whereas 64% of cases with relative gene loss by FISH (9 of 14) had no protein detectable by IHC (P ¼ 0.0005; Student's T-test). PCM1 encodes a 228 kDa centrosomal protein which exhibits cell cycle-dependent association with the centrosome complex (Balczon et al., 1994; Li et al., 2001; Dammermann and Merdes, 2002) , and is thought to play an important role in centriolar replication (Kubo and Tsukita, 2003) . Aberrant centrosome activity and structure (Lingle and Salisbury, 1999) have been associated with tumor progression. Despite the absence of previous documentation of PCM1 involvement in breast carcinogenesis, loss of heterozygosity has been detected in between 33 and 42% of breast cancer samples using the intragenic microsatellite marker D8S261 (Adelaide et al., 1998; Yokota et al., 1999; Sigbjornsdottir et al., 2000; Charafe-Jauffret et al., 2002) . Importantly, we demonstrate loss of PCM1 protein in a similar number (31%) of breast cancer samples, many of which showed concomitant reduced gene copy number by FISH. Taken together, our data therefore suggest that PCM1 is a potential TSG on 8p.
Loss of the normal cytoplasmic DUSP4/MKP-2 protein expression by IHC was seen in 34% of tumor samples (39/115; Figure 3c ). A total of 29 cases had data on both DUSP4/MKP-2 protein and gene copy number. DUSP4/MKP-2 protein was present in 90% (19 of 21) of cases with normal gene copy number detected by FISH. In all, 50% of cases with relative gene loss by FISH had no detectable protein by IHC (four of eight; P ¼ 0.05). DUSP4/MKP-2 is a dual-specificity phosphatase of the activated MAP kinases ERK1 and ERK2, which play an essential role in mitogen-regulated growth factor signal transduction. Expression of DUSP4/MKP-2 in mammalian cells has been shown to block activation of a MAP kinase-regulated reporter gene (Guan and Butch, 1995) , consistent with the notion that DUSP4/MKP-2 dephosphorylates and thus inactivates specific MAP kinases. DUSP4/MKP-2 has been recently identified as being overexpressed in a series of 12 human breast cancers, where it was hypothesized that DUSP4/ MKP-2 had a role in regulating the activity of the activated MEK/ERK signaling pathway (Wang et al., 2003) . Since all of the cancer samples in the Wang et al. (2003) study showed an increase in expression of ERK1&2, compared with matched normal breast, DUSP4/MKP-2 overexpression is likely to have been due to physiological upregulation. Our findings of loss of DUSP4/MKP-2 gene copy number by FISH, resultant lower expression level and loss of protein in a proportion of breast cancer samples compared with normal breast epithelium would suggest that DUSP4/ MKP-2 is more likely to have a TSG function. Loss of DUSP4/MKP-2 would then fail to inhibit the function of an inappropriately activated MEK/ERK pathway, such as would result from several well-documented oncogene-based cellular transformation events (Santen et al., 2002) .
Several other genes on 8p have been previously proposed to be TSGs in breast and other cancers (Saito et al., 1997; Matsushima et al., 1998) . Our data showed no differential gene expression of the previously nominated TSGs on 8p, EXTL3, NRG1 and the TRAIL receptor DR5 (Ugolini et al., 1999; Thor et al., 2002) . However, the gene expression analysis described herein was primarily designed to identify genes underlying the molecular dichotomy between two breast cancer types, rather than to identify TSGs in breast cancer in general.
In conclusion, our study demonstrates the existence of several candidate TSGs residing on chromosome 8p which may contribute to the molecular pathogenesis of early-onset/high-grade breast cancers.
